Key Insights

Highlights

Success Rate

96% trial completion (above average)

Research Maturity

52 completed trials (18% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.7%

2 terminated out of 295 trials

Success Rate

96.3%

+9.8% vs benchmark

Late-Stage Pipeline

6%

18 trials in Phase 3/4

Results Transparency

6%

3 of 52 completed with results

Key Signals

3 with results96% success

Data Visualizations

Phase Distribution

213Total
Not Applicable (38)
Early P 1 (3)
P 1 (41)
P 2 (113)
P 3 (13)
P 4 (5)

Trial Status

Recruiting112
Unknown66
Completed52
Not Yet Recruiting40
Active Not Recruiting14
Enrolling By Invitation4

Trial Success Rate

96.3%

Benchmark: 86.5%

Based on 52 completed trials

Clinical Trials (295)

Showing 20 of 20 trials
NCT07267000Not ApplicableRecruiting

EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER

NCT07359040Recruiting

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

NCT07499128Not ApplicableEnrolling By Invitation

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

NCT07617818Phase 2Not Yet Recruiting

QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer

NCT05375734Phase 2Completed

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

NCT07538479Phase 1Recruiting

Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)

NCT07475403Phase 2Recruiting

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

NCT05848011Phase 2Completed

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05034289Not ApplicableCompleted

Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy

NCT07113275Phase 3Recruiting

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer

NCT07581080Not ApplicableRecruiting

Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study

NCT07280715Not ApplicableNot Yet Recruiting

Investigating Real-Time Immunotherapy Symptoms Study

NCT07062055Phase 2Recruiting

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

NCT07565532Recruiting

Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment

NCT07040956Phase 2Recruiting

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

NCT06461780Recruiting

Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy

NCT05520099Active Not RecruitingPrimary

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

NCT06743555Phase 1Not Yet Recruiting

Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study

NCT07354971Recruiting

IMMUNO-FIT Observational Study

NCT06356584Phase 2Recruiting

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

Scroll to load more

Research Network

Activity Timeline